Jinyu Bio-Technology Co (SHSE:600201) EBIT : ¥310 Mil (TTM As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Jinyu Bio-Technology Co EBIT?

Jinyu Bio-Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥124 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥310 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jinyu Bio-Technology Co's annualized ROC % for the quarter that ended in Mar. 2024 was 8.21%. Jinyu Bio-Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 22.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jinyu Bio-Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.30%.

Jinyu Bio-Technology Co EBIT Historical Data

The historical data trend for Jinyu Bio-Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jinyu Bio-Technology Co EBIT Chart

Jinyu Bio-Technology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

262.75

477.19

413.32

250.40

315.88

Jinyu Bio-Technology Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															129.25	25.22	176.33	-14.91	123.60

Competitive Comparison of Jinyu Bio-Technology Co's EBIT

For the Biotechnology subindustry, Jinyu Bio-Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jinyu Bio-Technology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jinyu Bio-Technology Co's EV-to-EBIT falls into.

Jinyu Bio-Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥310 Mil.

Jinyu Bio-Technology Co (SHSE:600201) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jinyu Bio-Technology Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	429.548 * ( 1 - 13.78% )	/	( (4445.467	+	4576.722)	/ 2 )
=	370.3562856	/	4511.0945
=	8.21 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6872.582	-	677.647	-	( 1749.468	-	max(0, 840.446	-	3015.892	+	1749.468	))
=	4445.467

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6920.701	-	623.943	-	( 1720.036	-	max(0, 774.311	-	2882.774	+	1720.036	))
=	4576.722

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jinyu Bio-Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	494.404	/	( ( (1892.43 + max(381.508, 0))	+	(1884.181 + max(332.705, 0)) )	/	2 )
=	494.404	/	( ( 2273.938	+	2216.886 )	/	2 )
=	494.404	/	2245.412
=	22.02 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(857.494	+	322.254	+	40.674)	-	(677.647	+	0	+	161.267)
=	381.508

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(755.472	+	301.037	+	48.905)	-	(623.943	+	0	+	148.766)
=	332.705

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jinyu Bio-Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	310.236	/	7213.704
	=	4.30 %

Jinyu Bio-Technology Co EBIT Related Terms

Thank you for viewing the detailed overview of Jinyu Bio-Technology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Jinyu Bio-Technology Co (SHSE:600201) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jinyu Bio-Technology Co Ltd (SHSE:600201) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

No.1, Jinyu Street, Shaeryu Industrial Park, Economic and Technological Development Zone, Inner Mongolia Autonomous Region, Hohhot, CHN, 010030

Website

http://www.jinyu.com.cn

Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.

Executives

Zhang Chong Yu	Director
Zhang Jing	Directors, senior managers
Yang Zhao	senior management
Li Rong	senior management
Zhang Zhan Fu	Supervisors
Wei Xue Feng	Director
Wang Yong Sheng	Directors, senior managers
Yin Song Tao	Directors, senior managers
Liu Guo Ying	Supervisors
Zhang Hong Mei	senior management
Wen Li Min	Director
Xu Xian Ming	Director
Xu Shi Jun	Director
Wang Xiu Hua	Director
Li Shu Jian	senior management

Jinyu Bio-Technology Co (SHSE:600201) Headlines

No Headlines